Hamlet BioPharma AB publ (FRA:7ZT) EPS without NRI: €-0.03 (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7ZT Hamlet BioPharma AB publ FRA:7ZT
31 GF Score
Price €0.58
! 2 Warning Signs
View Full Analysis

What is Hamlet BioPharma AB publ EPS without NRI?

Hamlet BioPharma AB publ FRA:7ZT -2.04% 31 EPS without NRI is €-0.03 as of Mar. 2026. GuruFocus rates FRA:7ZT with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,161 Biotechnology companies, Hamlet BioPharma AB publ ranks better than 78.38% on this metric.

Hamlet BioPharma AB publ's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.01. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.03.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 41.00% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Hamlet BioPharma AB publ's EPS without NRI or its related term are showing as below:

FRA:7ZT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -203.7   Med: -8.15   Max: 77.9
Current: 41

During the past 13 years, Hamlet BioPharma AB publ's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 77.90% per year. The lowest was -203.70% per year. And the median was -8.15% per year.

FRA:7ZT's 3-Year EPS without NRI Growth Rate is ranked better than
78.38% of 1161 companies
in the Biotechnology industry
Industry Median: 16.2 vs FRA:7ZT: 41.00

Hamlet BioPharma AB publ's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.03.

Hamlet BioPharma AB publ's EPS (Basic) for the three months ended in Mar. 2026 was €-0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.03.


Hamlet BioPharma AB publ  (FRA:7ZT) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Hamlet BioPharma AB publ EPS without NRI Related Terms


Hamlet BioPharma AB publ EPS without NRI Historical Data

* Premium members only.

The historical data trend for Hamlet BioPharma AB publ's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hamlet BioPharma AB publ EPS without NRI Chart

Hamlet BioPharma AB publ Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.14 -0.02 -0.02 -0.03

Hamlet BioPharma AB publ Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.01 -0.01 -0.01 -0.01 -0.01

FRA:7ZT vs VRTX, REGN, RVMD: EPS without NRI Comparison

For the Biotechnology subindustry, Hamlet BioPharma AB publ's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hamlet BioPharma AB publ PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hamlet BioPharma AB publ's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Hamlet BioPharma AB publ's PE Ratio without NRI falls into.


FRA:7ZT
31GF Score
Hamlet BioPharma AB publ FRA:7ZT
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hamlet BioPharma AB publ EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.03 mean?
Hamlet BioPharma AB publ (FRA:7ZT) has a EPS without NRI of €-0.03 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Hamlet BioPharma AB publ and its competitors. According to the industry distribution chart, Hamlet BioPharma AB publ ranks #251 out of 1161 companies in the Biotechnology industry, placing it in the top 21.6%.
Is Hamlet BioPharma AB publ's EPS without NRI too high?
Hamlet BioPharma AB publ's current EPS without NRI is €-0.03. Based on the distribution chart, Hamlet BioPharma AB publ ranks #251 out of 1161 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hamlet BioPharma AB publ has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Hamlet BioPharma AB publ's EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hamlet BioPharma AB publ ranks #251 out of 1161 companies for EPS without NRI. This places Hamlet BioPharma AB publ in the top 22% of its industry — outperforming the majority of peers. The industry median EPS without NRI is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Hamlet BioPharma AB publ and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hamlet BioPharma AB publ's current EPS without NRI is €-0.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hamlet BioPharma AB publ stock overvalued right now?
Hamlet BioPharma AB publ (FRA:7ZT) has a current EPS without NRI of €-0.03. The current EPS without NRI is €-0.03. Hamlet BioPharma AB publ's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Hamlet BioPharma AB publ (FRA:7ZT), the current EPS without NRI is €-0.03 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Hamlet BioPharma AB publ Business Description

Other Exchanges HAMLET B:Sweden
Address Klinikgatan 32, BMC D10, Lund, SWE, SE-222 42
Hamlet BioPharma AB publ is a pharmaceutical company engaged in the research and development of drugs used for curing cancer.
31GF Score

Get the complete analysis for FRA:7ZT

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.58
Price